Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Hold” by Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF) has been assigned a consensus recommendation of “Hold” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company.

ZLDPF has been the topic of several research analyst reports. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Zacks Research downgraded Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 13th. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wolfe Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock opened at $47.73 on Monday. Zealand Pharma A/S has a one year low of $35.93 and a one year high of $83.12. The firm has a 50-day moving average of $47.31 and a 200-day moving average of $47.72. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The company has a market cap of $3.41 billion, a P/E ratio of 7.92 and a beta of 0.89.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.